ReviewAnnals of gastroenterological surgery2024
Incidence, mortality, survival, and treatment statistics of cancers in digestive organs-Japanese cancer statistics 2024.
Review in Annals of gastroenterological surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comprehensive Computed Tomography Evaluation of Gastric Cancer: 2026 Consensus Recommendation From the Korean Society of Abdominal Radiology.Korean journal of radiology · 2026Guideline
- Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Trial
- Intraoperative corticosteroid administration for resectable gastric cancer: a multicenter, randomized, open-label, phase II/III study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Trial
- Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025Trial
- Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801.International journal of clinical oncology · 2026Article
- CD86-Positive Mature Tertiary Lymphoid Structures Are Associated With CD8Annals of gastroenterological surgery · 2026Article
- Proportion of Screen-Detected Gastrointestinal Cancers From the National Cancer Registry in Japan.Cancer science · 2026Article
- Clinical and Functional Impact of CHMP3 in Pancreatic Ductal Adenocarcinoma.Annals of surgical oncology · 2026Article
- Association between fibroblast activation protein α expression and immune environment in gastric cancer.Oncology letters · 2026Article
- Identification of the novel therapeutic target gene SLC12A9, which determines the prognosis of patients with colorectal cancer.Surgery today · 2026Article
- Differential Prognostic Impact of Prior Cholecystectomy Between Proximal and Distal Colorectal Cancer: A 12-Year Retrospective Cohort Study of 3487 Consecutive Patients.Annals of gastroenterological surgery · 2026Article
- Japanese prospective registry study of particle therapy for esophageal cancer including comparison with clinical trials in Japan.Esophagus : official journal of the Japan Esophageal Society · 2026Observational
- 5-ALA in Oncology: Current Clinical Applications, Biological Limitations, and Emerging Translational Strategies.Biomedicines · 2026Review
- Intraperitoneal blue LED irradiation as a potential approach to suppress gastric cancer peritoneal dissemination in a murine model.Scientific reports · 2026Article
- Subsite- and histology-specific epidemiology of head and neck cancers in Japan from 2016 to 2019: an application of a new classification of rare cancers.International journal of clinical oncology · 2026Review
- Early increase of CD103 expression on peripheral PD-1Cancer immunology, immunotherapy : CII · 2026Observational
- Targeting regulatory T cells in gastrointestinal cancers: current status and future perspectives.International journal of clinical oncology · 2026Review
- Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer.International journal of clinical oncology · 2026Article
- Prognostic Impact of Immunoscore in Pathological Stage III Differentiated Gastric Cancer: A Multicenter Cohort Study Including PD-L1/PD-L2 Expression Analysis.Annals of gastroenterological surgery · 2026Article
- Influence of Hospital and Surgeon Volumes on Clinical Outcomes After Standard Surgery for Advanced Gastric Cancer: Supplementary Analysis of the Multicenter Randomized Phase III Trial JCOG1001.Annals of gastroenterological surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Access to accurate statistical data is paramount in the pursuit of effective cancer control activities, including research, policy development, and clinical care. This paper presents a comprehensive statistical report on the incidence, mortality, survival, and treatment of major digestive organ cancers, including those of the esophagus, stomach, colon, rectum, liver, extrahepatic biliary tract, and pancreas, in Japan. We compiled data from the National Cancer Center's "Cancer Information Services" and government "e-Stat" websites and offered a succinct overview of basic statistics by using tables and graphical presentations. Our findings underscore the critical role of the National Cancer Registry introduced by the Cancer Registry Act of 2016, which mandates hospitals across Japan to report cancer cases. This system ensures more accurate incidence statistics. Mortality data sourced from the National Vital Statistics System and survival rates derived from hospital-based cancer registries offer insights into the outcomes and efficacy of treatment modalities. These data indicate a downward trend in mortality for stomach and liver cancers and stable or declining rates for other cancers except pancreatic cancer, which has the lowest survival rate. Treatment patterns indicate an increase in endoscopic procedures for esophageal and stomach cancers, with stable treatment approaches for colorectal cancer. This statistical overview aims to improve the understanding and inform research, policy, and clinical decisions in the field of digestive organ cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.